Lumos Pharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company focused on rare disease therapeutics, will participate in two virtual investor conferences in September 2020. At the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, Lumos will present on September 14 at 4:30 PM ET and host one-on-one meetings. Additionally, at the Cantor Virtual Global Healthcare Conference on September 15-17, they will present on September 17 at 8:40 AM ET. Webcasts of both presentations will be available on their website.

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September:

• H.C. Wainwright 22^nd Annual Global Investment Conference – September 14-16, 2020

• Lumos Pharma is scheduled to present Monday, September 14^th, at 4:30PM ET
• Management will be available for virtual one-on-one meetings September 14^th – 16^th

• Cantor Virtual Global Healthcare Conference – September 15-17, 2020

• Lumos Pharma is scheduled to present Thursday, September 17^th, at 8:40AM ET
• Management will be available for virtual one-on-one meetings September 17^th throughout the day

Please contact your HC Wainwright and Cantor Fitzgerald sales representatives to participate in their investor conferences and to schedule a virtual one-on-one meeting with our management team. 

Live webcasts of each presentation will be available on the Company’s website in the “Investors & Media” section under “Events and Presentations.” An archived edition of the presentation will be available on the Company’s website later in the day on each day Lumos Pharma presents.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What investor conferences will Lumos Pharma participate in September 2020?

Lumos Pharma will participate in the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference.

When is Lumos Pharma presenting at the H.C. Wainwright Conference?

Lumos Pharma is scheduled to present on September 14, 2020, at 4:30 PM ET.

When will Lumos Pharma present at the Cantor Virtual Global Healthcare Conference?

Lumos Pharma will present on September 17, 2020, at 8:40 AM ET.

How can investors schedule meetings with Lumos Pharma management during the conferences?

Investors can contact their HC Wainwright and Cantor Fitzgerald sales representatives to schedule virtual one-on-one meetings.

Where can I find the webcasts of Lumos Pharma's presentations?

Live webcasts will be available in the "Investors & Media" section on Lumos Pharma’s website.